White Peony

Paeoniflorin and total glucosides of peony (TGP) exert immunomodulatory effects, including modulation of regulatory T-cells, suppression of Th17 responses, and alteration of cytokine profiles (TNF-α, IL-6, IL-17). These pharmacodynamic effects may partially antagonize immunosuppressive drug regimens by restoring immune activity. In autoimmune conditions, White Peony is sometimes co-prescribed, but in organ transplant or severe autoimmune disease managed with cyclosporine/tacrolimus, the interaction could reduce drug efficacy. Albiflorin also modulates CYP3A4, potentially altering cyclosporine pharmacokinetics.

Avoid combining White Peony preparations with cyclosporine or tacrolimus in solid-organ transplant patients without transplant team guidance. In autoimmune conditions, monitoring for breakthrough inflammation or rejection signs is essential. Review potential immunostimulatory effects of any TCM formula containing Paeonia lactiflora when patients are on immunosuppression.

Paeoniflorin has documented anti-thrombotic activity, inhibiting platelet aggregation through multiple mechanisms including reducing thromboxane B2 production, inhibiting ADP-induced platelet activation, and reducing fibrin clot formation. When combined with warfarin or antiplatelet agents, additive anti-thrombotic effects increase bleeding risk. Additionally, albiflorin modulates CYP2C9 at higher concentrations in vitro, which could theoretically affect warfarin metabolism.

Monitor INR in patients on warfarin who also take Paeonia lactiflora preparations. Monitor for signs of bleeding (bruising, prolonged bleeding from minor cuts, blood in urine/stool). Advise patients to discontinue at least 2 weeks prior to elective surgery. Use with caution alongside aspirin or clopidogrel.

Both paeoniflorin and albiflorin regulate CYP3A4 and CYP2D6 activity in vitro in human hepatoma HepG2 cells. Albiflorin showed significant induction or inhibition of CYP3A4 protein level depending on concentration (10⁻⁷ to 10⁻⁵ M range), while paeoniflorin showed minimal protein-level effects but did affect enzyme activity in P450-Glo assays. The clinical significance at standard medicinal doses is uncertain, but caution is warranted for narrow-therapeutic-index CYP3A4/CYP2D6 substrates.

At standard herbal doses, CYP interaction risk with White Peony is low but not negligible for sensitive substrates. Monitor for altered drug effects with simvastatin, midazolam, or haloperidol if high-dose White Peony preparations are used. Consult with a pharmacist regarding specific drug combinations in high-risk patients.

Paeoniflorin modulates the HPA axis, reduces corticosterone, and exerts antidepressant-like effects via serotonergic synapse modulation (serotonergic synapse pathway is identified as a key target in network pharmacology analysis). Preclinical data show additive or synergistic effects when paeoniflorin is combined with fluoxetine in depression models. While clinically the combination may provide benefit, the possibility of mild serotonin pathway summation should be considered.

White Peony is sometimes used alongside SSRIs in TCM integrative practice. At standard doses, the combination appears safe, but patients should be monitored for mild serotonergic symptoms if high doses are used. This is an area where clinical monitoring is appropriate rather than prohibition. Report unusual mood changes, agitation, or unusual sleep patterns.

Paeoniflorin has demonstrated hypoglycemic effects in preclinical studies via multiple mechanisms including improved insulin sensitivity, activation of AMPK pathways, and modulation of hepatic glucose metabolism. As a liver X receptor (LXR) agonist, paeoniflorin also affects lipid and glucose metabolism pathways. Additive blood glucose-lowering effects when combined with metformin or insulin may increase risk of hypoglycemia in patients with Type 2 diabetes.

Monitor fasting blood glucose and HbA1c periodically in diabetic patients using White Peony preparations alongside antidiabetic medications. Reduce antidiabetic dose proactively if hypoglycemia episodes occur. This combination could be beneficial in a supervised clinical context; avoid unmonitored combination in insulin-dependent diabetics.